The Healing Power of Botanical Therapeutics®

Company Contact:

Dr. Agnes P. Olszewski

President & CEO

Tel: (201) 647.3757

HERBORIUM GROUP, INC. RAISING FUNDS FOR AN AGGRESSIVE GROWTH PLAN

SADDLE BROOK, NJ, December 10, 2009 -- Herborium Group, Inc. (HBRM),(www.herborium.com) is a botanical therapeutics® company focusing on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and health care professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements) The Market potential for this sector worldwide is over $250 Billion annually with over $60 Billion a year spent already in the USA in a natural and alternative health sector. The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage.  Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce products to the Western markets. These unique capabilities mitigate risk, decrease development costs and speed up time to market. The Company has developed  a pipeline of botanical ingredient based products in the areas of dermatological needs (Acne and Rosacea with close to a $1 billion market potential), Prostate Health (BPH), Liver Diseases, Women’s Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. The company’s dermatological product AcnEase® (www.acnease.com)  is already established in a market; other botanical therapeutics® are ready to market and will be introduced upon receipt of necessary capital funds. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, clinics, specialty retailers, and e-commerce.

“Herborium has raised over $650,000 in funds to date in Private Placement but seeks additional capital funding. With additional capital the Company will be able to pursue an aggressive path of exponential growth leading to new product introduction and greater multiples of sales” said Dr. Olszewski, CEO and the President of the Company.”Our business plan calls for Herborium, upon the receipt of additional capital, to generate $10 million in sales in 2010 at a very attractive gross profit margin of 68%, and over $20 million in sales with a similar very attractive gross profit margin in 2011. 

The Company recently elected to have its Common-Stock traded for Pink Sheets in order to reduce operating expenses which it can better use for marketing and operational capital. However Herborium intends to maintain regular reporting to its shareholders and the financial industry and is committed to return to NASDAQ when appropriate.

“In these difficult economic times” said Dr. Olszewski, we need to be very prudent to use every dollar to grow the Company and create investors value by limiting other spending while growing sales and bringing new products to the market. ”

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995.  In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements.  The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control.  The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements.  The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent form 10-Q.